CN101069692A - 含积雪草总甙的药物制剂及其制备方法 - Google Patents
含积雪草总甙的药物制剂及其制备方法 Download PDFInfo
- Publication number
- CN101069692A CN101069692A CN 200610050614 CN200610050614A CN101069692A CN 101069692 A CN101069692 A CN 101069692A CN 200610050614 CN200610050614 CN 200610050614 CN 200610050614 A CN200610050614 A CN 200610050614A CN 101069692 A CN101069692 A CN 101069692A
- Authority
- CN
- China
- Prior art keywords
- triterpenes
- pharmaceutical preparation
- total
- gross weight
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title description 4
- 241000167550 Centella Species 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003921 oil Substances 0.000 claims abstract description 21
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 15
- 239000002562 thickening agent Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 150000003648 triterpenes Chemical class 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 230000002421 anti-septic effect Effects 0.000 claims description 12
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- -1 fatty acid ester Chemical class 0.000 claims description 7
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003961 penetration enhancing agent Substances 0.000 claims description 6
- 229920002545 silicone oil Polymers 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229940113171 polysorbate 85 Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 244000146462 Centella asiatica Species 0.000 abstract description 4
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 230000003204 osmotic effect Effects 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 description 20
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 12
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 11
- 229940022757 asiaticoside Drugs 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
具体成分 | 重量(g) | |
水相 | 积雪草总甙 | 5.0 |
Carbopol 934 | 0.6 | |
甘油 | 8.0 | |
去离子水 | 144.0 | |
油相 | 天然乳化剂(DRA-CE) | 10.0 |
辛酸葵酸三甘油脂 | 20.0 | |
C16-18混合醇 | 2.0 | |
棕榈酸异辛酯 | 8.0 | |
硅油200/100 | 1.0 | |
Novemer EC-1 | 0.2 | |
防腐剂、碱化剂 | Glydant Plus | 0.8 |
99%三乙醇胺 | 0.7 |
具体成分 | 重量(g) | |
水相 | 积雪草总甙 | 5.0 |
甘油 | 4.0 | |
去离子水 | 100.0 | |
油相 | 天然乳化剂(DRA-CE) | 5.0 |
辛酸葵酸三甘油脂 | 6.0 | |
C16-18混合醇 | 1.0 | |
棕榈酸异辛酯 | 4.0 | |
Carbopol 934 | 0.3 | |
硅油200/100 | 0.5 | |
Novemer EC-1 | 2 | |
防腐剂、碱化剂 | Glydant Plus | 0.4 |
99%三乙醇胺 | 0.3 |
时间(月) | 批号 | 鉴别 | 性状 | 微生物限度 | 积雪甙含量(%) |
0 | 001218 | 符合规定 | 白色软膏 | 符合规定 | 35.55 |
001219 | 符合规定 | 白色软膏 | 符合规定 | 35.07 | |
001220 | 符合规定 | 白色软膏 | 符合规定 | 34.83 | |
6 | 001218 | 符合规定 | 白色软膏 | 符合规定 | 33.62 |
001219 | 符合规定 | 白色软膏 | 符合规定 | 33.38 | |
001220 | 符合规定 | 白色软膏 | 符合规定 | 33.15 | |
12 | 001218 | 符合规定 | 白色软膏 | 符合规定 | 34.14 |
001219 | 符合规定 | 白色软膏 | 符合规定 | 34.22 | |
001220 | 符合规定 | 白色软膏 | 符合规定 | 33.72 | |
24 | 001218 | 符合规定 | 白色软膏 | 符合规定 | 35.36 |
001219 | 符合规定 | 白色软膏 | 符合规定 | 35.09 | |
001220 | 符合规定 | 白色软膏 | 符合规定 | 34.81 |
时间(h) | 累计释药量 | 累积释药百分率 |
0 | 0 | 0 |
0.5 | 18.7 | 18.7 |
1 | 27.5 | 27.5 |
2 | 35.7 | 35.7 |
4 | 42.3 | 42.3 |
8 | 47.8 | 47.8 |
12 | 52.1 | 52.1 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100506146A CN101069692B (zh) | 2006-05-08 | 2006-05-08 | 含积雪草总甙的药物制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100506146A CN101069692B (zh) | 2006-05-08 | 2006-05-08 | 含积雪草总甙的药物制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101069692A true CN101069692A (zh) | 2007-11-14 |
CN101069692B CN101069692B (zh) | 2011-04-20 |
Family
ID=38897209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100506146A Active CN101069692B (zh) | 2006-05-08 | 2006-05-08 | 含积雪草总甙的药物制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101069692B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191163A (zh) * | 2013-04-29 | 2013-07-10 | 崔新明 | 一种皮肤创面修复药物组合物 |
CN103494877A (zh) * | 2013-09-25 | 2014-01-08 | 南阳市汇博生物技术有限公司 | 一种用于治疗疤痕的组合物及其制备方法 |
WO2018106107A1 (en) * | 2016-12-06 | 2018-06-14 | Kopsky David Jos | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
CN110201217A (zh) * | 2019-06-13 | 2019-09-06 | 西安医学院 | 一种用于宫颈糜烂术后创伤出血的止血微球及其制备方法 |
CN111481528A (zh) * | 2020-03-23 | 2020-08-04 | 北京和正堂生物科技有限公司 | 基于穴位经皮给药的药物载体与药物组合物及其制备方法与应用 |
US11147799B2 (en) | 2016-12-06 | 2021-10-19 | Jan Marius Keppel Hesselink | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain |
-
2006
- 2006-05-08 CN CN2006100506146A patent/CN101069692B/zh active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103191163A (zh) * | 2013-04-29 | 2013-07-10 | 崔新明 | 一种皮肤创面修复药物组合物 |
CN103494877A (zh) * | 2013-09-25 | 2014-01-08 | 南阳市汇博生物技术有限公司 | 一种用于治疗疤痕的组合物及其制备方法 |
CN103494877B (zh) * | 2013-09-25 | 2016-01-27 | 南阳市汇博生物技术有限公司 | 一种用于治疗疤痕的组合物及其制备方法 |
WO2018106107A1 (en) * | 2016-12-06 | 2018-06-14 | Kopsky David Jos | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
US11147799B2 (en) | 2016-12-06 | 2021-10-19 | Jan Marius Keppel Hesselink | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain |
US11285099B2 (en) | 2016-12-06 | 2022-03-29 | Topical Innovations B.V. | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
CN110201217A (zh) * | 2019-06-13 | 2019-09-06 | 西安医学院 | 一种用于宫颈糜烂术后创伤出血的止血微球及其制备方法 |
CN110201217B (zh) * | 2019-06-13 | 2021-12-07 | 西安医学院 | 一种用于宫颈糜烂术后创伤出血的止血微球及其制备方法 |
CN111481528A (zh) * | 2020-03-23 | 2020-08-04 | 北京和正堂生物科技有限公司 | 基于穴位经皮给药的药物载体与药物组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101069692B (zh) | 2011-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101069692B (zh) | 含积雪草总甙的药物制剂及其制备方法 | |
CN101569640A (zh) | 积雪草总苷用于制备预防或治疗妊娠纹的药物或化妆品的用途 | |
CN104981258A (zh) | 用于组织再生的组合物和方法 | |
CN101310734A (zh) | 用于治疗奶牛子宫内膜炎的中西药复方子宫灌注液 | |
CN105726586A (zh) | 银杏提取物的外用制剂、其制备方法及用途 | |
CN114146051A (zh) | 生肌愈疡中药凝胶剂及其制备方法 | |
CN105411998B (zh) | 含有五味子乙素的治疗烧烫伤的外用组合物 | |
WO1998018478A1 (fr) | Huiles de tortues terrestres et marines, compositions les contenant et leur procede de preparation | |
CN111700846A (zh) | 一种舒缓型光子冷凝胶及其制备方法 | |
CN107823124B (zh) | 一种盐酸奥洛他定外用组合物及其乳膏剂 | |
CN101536977A (zh) | 3β,12,13-三羟基-齐墩果烷-28-酸为活性成分的凝胶 | |
CN108853369A (zh) | 天然植物抗菌液PAMs水凝胶贴剂的制备方法及应用 | |
CN109528693A (zh) | 一种雷帕霉素巴布剂及其制备方法 | |
CN110772473B (zh) | 一种合适于糖尿病病人皮肤的护肤品 | |
CN109200014B (zh) | 一种醋酸曲安奈德乳膏及其制备方法 | |
CN113559052A (zh) | 一种聚肌胞外用制剂及其制备方法 | |
CN115487112A (zh) | 用于皮肤抗炎舒缓的组合物 | |
CN114129629A (zh) | 一种痔疮凝胶及其制备方法 | |
CN100596279C (zh) | 治疗妇科炎症的妇康舒乳膏剂及其制备方法 | |
CN117815399A (zh) | 用于治疗特应性皮炎的组合物及其制备方法和用途 | |
CN114748527A (zh) | 一种治疗婴幼儿湿疹、皮炎的复方龙胆凝胶 | |
CN111905044A (zh) | 用于治疗硬皮病的药物组合物及其制备方法和应用 | |
CN112353859A (zh) | 一种含透明质酸的复配组合物及其在腹部按摩产品中的应用 | |
CN115844897A (zh) | 一种治疗敏感肌肤的外用制剂及其制备方法和用途 | |
CN101513415A (zh) | 1-羟基-齐墩果烷-28-羧酸甲酯-2,12-二烯在制备治疗皮肤疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG RUIDA PHARMACEUTICAL CO., LTD. HANGZHOU S Owner name: HAINAN PULIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20110801 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310009 HANGZHOU, ZHEJIANG PROVINCE TO: 571127 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110801 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Co-patentee after: Zhejiang Ruida Pharm Co.,Ltd. Patentee after: Hainan Poly Pharm Co.,Ltd. Co-patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 310009, 10, combed lane, Shangcheng District, Zhejiang, Hangzhou Patentee before: Fan Minhua |
|
C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: Zhejiang Ruida Pharm Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230116 Address after: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Address before: 571127 Guilin Ocean Economic and Technological Development Zone, Meilan District, Haikou City, Hainan Province Patentee before: HAINAN POLY PHARM. Co.,Ltd. Patentee before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhu Xulei Document name: Notification of Conformity |